143 related articles for article (PubMed ID: 2502924)
1. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
Jaffe GJ; Lewis H; Han DP; Williams GA; Abrams GW
Am J Ophthalmol; 1989 Aug; 108(2):170-5. PubMed ID: 2502924
[TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator for postvitrectomy fibrin formation.
Jaffe GJ; Abrams GW; Williams GA; Han DP
Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297
[TBL] [Abstract][Full Text] [Related]
3. [Tissue plasminogen activator treatment of postvitrectomy pupillary fibrin membrane].
Maeno T; Maeda N; Ikeda T; Tano Y
Nippon Ganka Gakkai Zasshi; 1991 Nov; 95(11):1124-8. PubMed ID: 1759654
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
Zhao P; Wang W
Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
[TBL] [Abstract][Full Text] [Related]
5. The use of tissue plasminogen activator in postvitrectomy cases.
Koutsandrea C; Apostolopoulos M; Theodossiadis P
Int Ophthalmol; 1993 Apr; 17(2):95-100. PubMed ID: 8407122
[TBL] [Abstract][Full Text] [Related]
6. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
Williams GA; Lambrou FH; Jaffe GA; Snyder RW; Green GD; Devenyi RG; Abrams GW
Arch Ophthalmol; 1988 Aug; 106(8):1055-8. PubMed ID: 3135790
[TBL] [Abstract][Full Text] [Related]
7. Management of fibrin pupillary-block glaucoma after pars plana vitrectomy with intravitreal gas injection.
Lewis H; Han D; Williams GA
Am J Ophthalmol; 1987 Feb; 103(2):180-2. PubMed ID: 3812619
[TBL] [Abstract][Full Text] [Related]
8. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.
Dabbs CK; Aaberg TM; Aguilar HE; Sternberg P; Meredith TA; Ward AR
Am J Ophthalmol; 1990 Oct; 110(4):354-60. PubMed ID: 2121038
[TBL] [Abstract][Full Text] [Related]
9. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Wu WC; Chang SM; Chen JY; Chang CW
J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
[TBL] [Abstract][Full Text] [Related]
10. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin.
Boldt HC; Abrams GW; Murray TG; Han DP; Mieler WF
Retina; 1992; 12(3 Suppl):S75-9. PubMed ID: 1455089
[TBL] [Abstract][Full Text] [Related]
11. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
Schmitz K; Greite JH; Bartenschlager EM
Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator treatment of postoperative intraocular fibrin.
Johnson RN; Olsen K; Hernandez E
Ophthalmology; 1988 May; 95(5):592-6. PubMed ID: 3140157
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
Koerner F; Boehnke M
Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
[TBL] [Abstract][Full Text] [Related]
14. The effect of tissue plasminogen activator on retinal bleeding.
Sternberg P; Aguilar HE; Drews C; Aaberg TM
Arch Ophthalmol; 1990 May; 108(5):720-2. PubMed ID: 2110447
[TBL] [Abstract][Full Text] [Related]
15. A malignant glaucoma-like syndrome following pars plana vitrectomy.
Massicotte EC; Schuman JS
Ophthalmology; 1999 Jul; 106(7):1375-9. PubMed ID: 10406625
[TBL] [Abstract][Full Text] [Related]
16. Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report.
Yoshino H; Seki M; Ueda J; Yoshino T; Fukuchi T; Abe H
BMC Ophthalmol; 2012 Mar; 12():3. PubMed ID: 22433746
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
Cellini M; Baldi A; Possati GL
Int Ophthalmol; 1994-1995; 18(6):351-3. PubMed ID: 7642335
[TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator in the treatment of vitreoretinal diseases.
Kamei M; Estafanous M; Lewis H
Semin Ophthalmol; 2000 Mar; 15(1):44-50. PubMed ID: 10749314
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
MacCumber MW; McCuen BW; Toth CA; Ferrone PJ; Jaffe GJ
Ophthalmology; 1996 Feb; 103(2):269-73. PubMed ID: 8594513
[TBL] [Abstract][Full Text] [Related]
20. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
Wedrich A; Menapace R; Mühlbauer-Ries E
Int Ophthalmol; 1994-1995; 18(5):277-80. PubMed ID: 7607808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
